Press Release

Neurological Biomarkers Market to Grow with a CAGR of 8.10% through 2030

Rising Prevalence of Neurological Disorders and Growing Aging Population are expected to drive the Global Neurological Biomarkers Market growth in the forecast period, 2026-2030

 

According to TechSci Research report, “Neurological Biomarkers Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Neurological Biomarkers Market stood at USD 8.70 Billion in 2024 and is anticipated to grow with a CAGR of 8.10% in the forecast period, 2026-2030.

The neurological biomarkers market is advancing rapidly, driven by continuous technological innovations in biomarker discovery, increased R&D investments, and the growing demand for personalized medicine. Breakthroughs in genomics, proteomics, metabolomics, and imaging techniques are significantly enhancing the precision and efficiency of biomarker-based diagnostics. Cutting-edge methodologies such as liquid biopsy, next-generation sequencing (NGS), and machine learning-driven biomarker analysis are making neurological biomarker detection more reliable, cost-effective, and scalable. These innovations enable early disease identification, improve patient stratification, and facilitate the development of targeted therapies, significantly transforming disease management in neurology.

Substantial investments from governments, pharmaceutical companies, and research institutions are further accelerating market expansion. The rising public and private funding for biomarker research and clinical trials, along with strategic collaborations between biotech firms and healthcare organizations, is leading to breakthrough discoveries in biomarker-based diagnostics and therapeutics. Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) are actively supporting biomarker-driven drug development, fast-tracking approvals for therapies that leverage biomarker insights. This regulatory backing is driving pharmaceutical companies to integrate biomarkers into their drug discovery pipelines, reducing development timelines, improving approval rates, and enhancing treatment efficacy.

The shift toward precision medicine is another major growth driver, as neurological biomarkers play a crucial role in tailoring treatment plans based on an individual’s genetic makeup and disease profile. Biomarkers facilitate early detection, prognosis assessment, and therapy monitoring, reducing trial-and-error approaches and leading to better clinical outcomes. Pharmaceutical companies are increasingly leveraging biomarkers to develop targeted therapies for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, which in turn minimizes treatment failures and optimizes drug performance. The adoption of biomarkers in drug development is growing, as they provide critical insights into drug efficacy, disease progression, and patient response. By serving as surrogate endpoints in clinical trials, biomarkers help pharmaceutical firms accelerate drug approvals, reduce trial failures, and streamline regulatory submissions. This trend is particularly evident in the development of biologics, gene therapies, and regenerative medicine, where precise biomarkers are essential for guiding therapeutic strategies.

Governments worldwide are playing a crucial role in fostering biomarker research by funding large-scale neuroscience projects and implementing policies that encourage biomarker-based diagnostics and therapeutics. Organizations such as the NIH, WHO, and the European Commission are supporting efforts to understand neurological diseases at a molecular level, paving the way for more effective treatments. Additionally, favorable policies around biomarker patenting, reimbursement for biomarker-based tests, and data-sharing initiatives are providing further momentum to market growth. The increasing global healthcare expenditure and rising awareness of neurodegenerative diseases are also driving demand for biomarker-based diagnostics. With higher investments in neurological healthcare infrastructure and an expanding patient population seeking early diagnostic solutions, biomarker-based tests are becoming more widely adopted. This trend is particularly prominent in emerging markets, where improved healthcare access is contributing to higher diagnosis rates and better disease management strategies.

The biotechnology and biopharmaceutical sectors are deeply invested in the neurological biomarkers market, integrating biomarker-based approaches into their drug development and commercialization strategies. Mergers, acquisitions, and strategic partnerships between biotech firms and pharmaceutical companies are fueling advancements in biomarker-driven therapies, strengthening the market’s growth trajectory. However, several challenges remain, including the complexity of neurological disorders, which makes it difficult to develop biomarkers with high specificity and reproducibility. Additionally, stringent regulatory approvals continue to pose a significant barrier, as biomarker validation processes are highly regulated, leading to long development timelines. Furthermore, the increasing reliance on AI-driven biomarker analysis raises concerns over patient data security and compliance, requiring robust data protection frameworks to ensure ethical and regulatory adherence.

Despite these challenges, the neurological biomarkers market is poised for sustained growth, with advancements in biomarker-based diagnostics, drug development, and personalized medicine driving its evolution. As the industry continues to innovate, biomarkers will play an increasingly critical role in transforming neurological disease management and therapeutic decision-making.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Neurological Biomarkers Market

 

The Global Neurological Biomarkers Market is segmented into type, application, end-user, regional distribution, and company

Based on its end user, The hospital & hospital laboratories segment is projected to experience rapid growth during the forecast period. Hospitals and hospital laboratories serve as vital hubs for diagnostic and clinical services. They are at the forefront of patient care, diagnosis, and treatment for a wide range of medical conditions, including neurological disorders. Neurological biomarkers are essential tools in diagnosing and monitoring these disorders, making hospitals and hospital laboratories the primary end-users for such biomarkers. Hospitals offer comprehensive patient care, making them ideal settings for neurological biomarker utilization. Patients with neurological disorders often require multidisciplinary care, including neurology, radiology, pathology, and neurosurgery. Hospital settings facilitate seamless collaboration among specialists, with biomarkers playing a pivotal role in guiding clinical decisions.

Hospitals typically house state-of-the-art imaging and testing equipment, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scanners, as well as advanced laboratory instruments. These facilities enable the acquisition of precise biomarker data, including imaging and laboratory-based biomarkers, contributing to accurate diagnosis and monitoring. Hospitals provide care for both acute and chronic neurological conditions. While acute cases may require immediate diagnosis and intervention, chronic conditions necessitate long-term monitoring. Biomarkers, including imaging, genetic, and proteomic biomarkers, are indispensable in both scenarios, allowing for timely treatment and disease management. These factors collectively contribute to the growth of this segment.

Based on region, The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Neurological Biomarkers players during the forecast period. Factors such as Many countries in the Asia-Pacific region are experiencing significant increases in healthcare expenditure. As a result, there is greater investment in healthcare infrastructure, research, and advanced diagnostic technologies, creating a conducive environment for biomarker adoption. Similar to North America, the Asia-Pacific region is also facing a demographic shift with a growing aging population. This demographic change is associated with an increased prevalence of neurological disorders, driving the demand for biomarkers. Emerging economies within the Asia-Pacific region, such as China and India, are witnessing rapid economic growth and urbanization. This growth is accompanied by improved access to healthcare services and increased awareness of neurological health.

 

Major companies operating in Global Neurological Biomarkers Market are:

  • PERKINELMER INC.
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific, Inc.
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. HOFFMANN-LA ROCHE LTD.
  • Merck & Co., Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Myriad Genetics, Inc.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Advancements in Diagnostic Technologies and Increased investment in neurological biomarker research and development by pharmaceutical companies are key drivers of the Neurological Biomarkers market. In recent years, the growing shift toward personalized medicine approaches emphasizes the importance of biomarkers in tailoring treatment plans to individual patients. Biomarkers enable the identification of patient-specific profiles, optimizing therapeutic outcomes and reducing adverse effects. Moreover, the growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Neurological Biomarkers and supplements market in the coming years”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

Neurological Biomarkers Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Imaging, Proteomic, Genomic, Metabolomic, Others), By Application (Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's Disease, Others), By End-User (Research Organizations, Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Others), By Region & Competition, 2020-2030F” has evaluated the future growth potential of Global Neurological Biomarkers Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Neurological Biomarkers Market.


Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com